Could gut bacteria help fight prostate cancer? new trial tests antibiotic combo

NCT ID NCT06126731

Recruiting now Disease control Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This trial tests whether a short course of four antibiotics can make the standard drug enzalutamide work better in men with metastatic castration-resistant prostate cancer. About 39 men will receive the antibiotics plus enzalutamide to see if the combination is safe and can shrink tumors or lower PSA levels. The goal is to improve disease control in this advanced stage of cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Amoxicillin, metronidazole, ciprofloxacin, vancomycin, and enzalutamide
What this could lead to: If it works, this could point toward a way to make enzalutamide more effective for men with advanced prostate cancer by targeting gut bacteria.
What could go wrong: This is an early, small trial (39 people) testing safety and effectiveness. The antibiotic combination may cause side effects or not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

Contacts and locations

Locations

Oncolgy Institute of Southern Switzerland (IOSI)
RECRUITING

Bellinzona, Switzerland
The Royal Marsden NHS Foundation Trust
RECRUITING

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.